Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
| Data(s) |
2012
|
|---|---|
| Resumo |
While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies. |
| Formato |
application/pdf |
| Identificador |
http://boris.unibe.ch/14037/1/Meyrat%20AlimentPharmacolTher%202012.pdf Meyrat, P; Safroneeva, E; Schoepfer, A M (2012). Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Alimentary pharmacology & therapeutics, 36(11-12), pp. 1084-93. Oxford: Wiley-Blackwell 10.1111/apt.12087 <http://dx.doi.org/10.1111/apt.12087> doi:10.7892/boris.14037 info:doi:10.1111/apt.12087 info:pmid:23066911 urn:issn:0269-2813 |
| Idioma(s) |
eng |
| Publicador |
Wiley-Blackwell |
| Relação |
http://boris.unibe.ch/14037/ |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Meyrat, P; Safroneeva, E; Schoepfer, A M (2012). Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Alimentary pharmacology & therapeutics, 36(11-12), pp. 1084-93. Oxford: Wiley-Blackwell 10.1111/apt.12087 <http://dx.doi.org/10.1111/apt.12087> |
| Palavras-Chave | #610 Medicine & health |
| Tipo |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion NonPeerReviewed |
